THThomas J. Hoerger

Thomas J. Hoerger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas J. Hoerger has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness

    by Thomas J. Hoerger, Rainer Hilscher, Simon Neuwahl, Matthew B. Kaufmann, Hui Shao, Michael Laxy, Yiling J. Cheng, Stephen Benoit, Haiying Chen, Andrea Anderson, et al.


  • Estimating costs of diabetes complications in people <65 years in the U.S. using panel data

    by Wenya Yang, Inna Cintina, Thomas Hoerger, Simon J. Neuwahl, Hui Shao, Michael Laxy, Ping Zhang


  • Economics and Policy in Bariatric Surgery

    by Thomas J. Hoerger

    The purpose of this review is to provide current synthesis of the evidence on the cost-effectiveness of bariatric surgery for persons with diabetes.


  • Scaling‐up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic

    by Hannah Fraser, Jon Zibbell, Thomas Hoerger, Susan Hariri, Claudia Vellozzi, Natasha K. Martin, Alex H. Kral, Matthew Hickman, John W. Ward, Peter Vickerman

    Background and aims: Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection among people who inject drugs (PWID) in rural settings of the United States. We determined the required scale‐up of HCV treatment with or without scale‐up of HCV prevention interventions to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025 and 2030 in a rural US setting.Design: An ordinary differential equation model of HCV transmission calibrated to HCV epidemiological data obtained primarily from an HIV outbreak investigation in Indiana.Setting: Scott County, Indiana (population 24 181), USA, a rural setting with negligible baseline interventions, increasing HCV epidemic since 2010, and 55.3% chronic HCV prevalence among PWID in 2015.Participants: PWID.Measurements: Required annual HCV treatments per 1000 PWID (and initial annual percentage of infections treated) to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025/30, either with or without scaling‐up syringe service programmes (SSPs) and medication‐assisted treatment (MAT) to 50% coverage. Sensitivity analyses considered whether this impact could be achieved without re‐treatment of re‐infections, and whether greater intervention scale‐up was required due to the increasing epidemic in this setting.Findings: To achieve a 90% reduction in incidence and prevalence by 2030, without MAT and SSP scale‐up, 159 per 1000 PWID (initially 24.9% of infected PWID) need to be HCV‐treated annually. However, with MAT and SSP scaled‐up, treatment rates are halved (89 per 1000 annually or 14.5%). To reach the same target by 2025 with MAT and SSP scaled‐up, 121 per 1000 PWID (19.9%) need treatment annually. These treatment requirements are threefold higher than if the epidemic was stable, and the impact targets are unattainable without retreatment.Conclusions: Combined scale‐up of hepatitis C virus treatment and prevention interventions is needed to decrease the increasing burden of hepatitis C virus incidence and prevalence in rural Indiana, USA, by 90% by 2025/30.


  • Open Access

    The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

    by On Behalf Of The Centers For Disease Control And Prevention Ckd Initiative, Benjamin O. Yarnoff, Thomas J. Hoerger, Siobhan K. Simpson, Alyssa Leib, Nilka R. Burrows, Sundar S. Shrestha, Meda E. Pavkov

    Better treatment during early stages of chronic kidney disease (CKD) may slow progression to end-stage renal disease and decrease associated complications and medical costs. Achieving early treatment of CKD is challenging, however, because a large fraction of persons with CKD are unaware of having this disease. Screening for CKD is one important method for increasing awareness. We examined the cost-effectiveness of identifying persons for early-stage CKD screening (i.e., screening for moderate albuminuria) using published CKD risk scores. We used the CKD Health Policy Model, a micro-simulation model, to simulate the cost-effectiveness of using CKD two published risk scores by Bang et al. and Kshirsagar et al. to identify persons in the US for CKD screening with testing for albuminuria. Alternative risk score thresholds were tested (0.20, 0.15, 0.10, 0.05, and 0.02) above which persons were assigned to receive screening at alternative intervals (1-, 2-, and 5-year) for follow-up screening if the first screening was negative. We examined incremental cost-effectiveness ratios (ICERs), incremental lifetime costs divided by incremental lifetime QALYs, relative to the next higher screening threshold to assess cost-effectiveness. Cost-effective scenarios were determined as those with ICERs less than $50,000 per QALY. Among the cost-effective scenarios, the optimal scenario was determined as the one that resulted in the highest lifetime QALYs. ICERs ranged from $8,823 per QALY to $124,626 per QALY for the Bang et al. risk score and $6,342 per QALY to $405,861 per QALY for the Kshirsagar et al. risk score. The Bang et al. risk score with a threshold of 0.02 and 2-year follow-up screening was found to be optimal because it had an ICER less than $50,000 per QALY and resulted in the highest lifetime QALYs. This study indicates that using these CKD risk scores may allow clinicians to cost-effectively identify a broader population for CKD screening with testing for albuminuria and potentially detect people with CKD at earlier stages of the disease than current approaches of screening only persons with diabetes or hypertension.


  • Open Access

    Can Incentives Improve Medicaid Patient Engagement and Prevent Chronic Diseases?

    by Thomas J. Hoerger, Rebecca Perry, Kathleen Farrell, Stephanie Teixeira-Poit

    Under the Medicaid Incentives for the Prevention of Chronic Diseases model, 10 states are testing whether incentives can encourage Medicaid beneficiaries to lose weight, stop smoking, work to prevent diabetes, or control risk factors for other chronic diseases. This commentary describes these incentive programs and how they will be evaluated.


  • Medicare’s Intensive Behavioral Therapy for Obesity

    by Thomas J. Hoerger, Wesley L. Crouse, Xiaohui Zhuo, Edward W. Gregg, Ann L. Albright, Ping Zhang


  • Top Cited Papers

    The Future Burden of CKD in the United States: A Simulation Model for the CDC CKD Initiative

    by Thomas J. Hoerger, Sean A. Simpson, Benjamin O. Yarnoff, Meda E. Pavkov, Nilka Ríos Burrows, Sharon H. Saydah, Desmond E. Williams, Xiaohui Zhuo


  • Cost-Effectiveness of Ensuring Hepatitis B Protection for Previously Vaccinated Healthcare Personnel

    by Thomas J. Hoerger, Christina Bradley, Sarah F. Schillie, Meredith Reilly, Trudy V. Murphy

    Objective: To examine the cost-effectiveness of pre- and postexposure approaches for ensuring hepatitis B protection among previously vaccinated healthcare personnel (HCP).Design: A decision-analytic model was developed for alternative strategies of ensuring hepatitis B protection under assumptions of 68% and 95% long-term protection after a primary vaccination series. Costs and quality-adjusted life years (QALYs) lost from infections were estimated, and incremental cost-effectiveness ratios (ICERs) were calculated relative to a no intervention alternative over 10 years of intervention. Separate analyses were performed for trainees and nontrainees, using the healthcare system perspective. Trainees face higher risk of exposure and likely received primary vaccination as infants.Setting: General healthcare settings.Participants: Trainee and nontrainee HCP.Interventions: Preexposure testing for antibody to hepatitis B surface antigen followed by additional vaccination for HCP without protective antibody levels; postexposure evaluation and management for HCP reporting blood or body fluid exposuresResults: The preexposure strategy prevents more infections and has higher costs than the postexposure strategy or no intervention. For trainees, 10-year preexposure evaluation ICERs are $832,875 and $144,457 per QALY for 95% and 68% long-term vaccine protection, respectively. Trainee 10-year postexposure evaluation ICERs are $1,146,660 and $191,579 per QALY under the 95% and 68% long-term protection assumptions, respectively. For nontrainees, 10-year ICERs are $745,739 and $1,129,286 per QALY for the preexposure and postexposure evaluation strategies, respectively.Conclusions: ICERs may inform decision makers as they decide whether the added cost of the preexposure strategy provides sufficient value in preventing infections.


  • Open Access

    Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes

    by Thomas J. Hoerger, Sarah Schillie, John S. Wittenborn, Christina L. Bradley, Fangjun Zhou, Kathy Byrd, Trudy V. Murphy

    OBJECTIVE To examine the cost-effectiveness of a hepatitis B vaccination program for unvaccinated adults with diagnosed diabetes in the U.S. RESEARCH DESIGN AND METHODS We used a cost-effectiveness simulation model to estimate the cost-effectiveness of vaccinating adults 20–59 years of age with diagnosed diabetes not previously vaccinated for or infected by hepatitis B virus (HBV). The model estimated acute and chronic HBV infections, complications, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Data sources included surveillance data, epidemiological studies, and vaccine prices. RESULTS With a 10% uptake rate, the intervention will vaccinate 528,047 people and prevent 4,271 acute and 256 chronic hepatitis B infections. Net health care costs will increase by $91.4 million, and 1,218 QALYs will be gained, producing a cost-effectiveness ratio of $75,094 per QALY gained. Results are most sensitive to age, the discount rate, the hepatitis B incidence ratio for people with diabetes, and hepatitis B infection rates. Cost-effectiveness ratios rise with age at vaccination; an alternative intervention that vaccinates adults with diabetes 60 years of age or older had a cost-effectiveness ratio of $2.7 million per QALY. CONCLUSIONS Hepatitis B vaccination for adults with diabetes 20–59 years of age is modestly cost-effective. Vaccinating older adults with diabetes is not cost-effective. The study did not consider hepatitis outbreak investigation costs, and limited information exists on hepatitis progression among older adults with diabetes. Partly based on these results, the Advisory Committee on Immunization Practices recently recommended hepatitis B vaccination for people 20–59 years of age with diagnosed diabetes.